Cytokinetics Inc vs iShares Semiconductor ETF — how do they compare? Cytokinetics Inc trades at $81.69 (market cap $11.12B), while iShares Semiconductor ETF trades at $553.31. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | SOXX | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $87.26 | $655.01 |
52-Week Low | $33.23 | $236.93 |
Enterprise Value | $11.59B | — |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
SOXX trades at $553.1, down 4.82% over 24 hours amid a broader semiconductor selloff. Technical indicators show a bearish trend with support at $530 and resistance at $557. The ETF has delivered exceptional YTD performance with 93.3% gains through July 6, 2026, driven by AI demand, though recent volatility has erased some gains. A dividend of $0.28 is scheduled for June 2026.
Outlook remains mixed with strong AI-driven growth potential offset by sector volatility and Michael Burry's bearish bet. Key risks include semiconductor cyclicality and geopolitical tensions. The ETF offers diversified exposure to leading chip companies but faces near-term pressure from the recent correction.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →